Global Monoclonal Antibody Service Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
- Published Date: 2021-04-23
- Report ID: 105717
- Pages: 113
-
Format:
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Monoclonal Antibody Service market in this environment.
In terms of revenue, this research report indicated that the global Monoclonal Antibody Service market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Monoclonal Antibody Service industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Pfizer aims at producing XX K Units Monoclonal Antibody Service in 2020, with XX % production to take place in global market, Roche accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Monoclonal Antibody Service Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Monoclonal Antibody Service Market
Pfizer
Roche
Eli Lilly
Bayer
Amgen
Sanofi-Aventis
Johnson & Johnson
Novo Nordisk
Merck
Abbott Laboratories
GSK
BMS
Alexion
UCB
Seattle Genetics
...
Major Type of Monoclonal Antibody Service Covered in Prudent Markets report:
Reagents
Drugs
Other
Application Segments Covered in Prudent Markets Market
Diagnostic Laboratories
Research & Academic Laboratories
Pharmaceutical & Biotechnology Companies
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Monoclonal Antibody Service Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Reagents -Product Introduction and Major Manufacturers
1.1.2 Drugs -Product Introduction and Major Manufacturers
1.1.3 Other -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Monoclonal Antibody Service Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis
3.1 China Monoclonal Antibody Service Market
3.1.1 Top Companies leading Monoclonal Antibody Service Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Monoclonal Antibody Service Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)
3.2 EU Monoclonal Antibody Service Market
3.2.1 Top Companies leading Monoclonal Antibody Service Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Monoclonal Antibody Service Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)
3.3 USA Monoclonal Antibody Service Market
3.3.1 Top Companies leading Monoclonal Antibody Service Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Monoclonal Antibody Service Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)
3.4 Japan Monoclonal Antibody Service Market
3.4.1 Top Companies leading Monoclonal Antibody Service Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Monoclonal Antibody Service Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)
3.5 India Monoclonal Antibody Service Market
3.5.1 Top Companies leading Monoclonal Antibody Service Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Monoclonal Antibody Service Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)
3.6 Southeast Asia Monoclonal Antibody Service Market
3.6.1 Top Companies leading Monoclonal Antibody Service Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Monoclonal Antibody Service Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Monoclonal Antibody Service Market
3.7.1 Top Companies leading Monoclonal Antibody Service Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Monoclonal Antibody Service Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)
4.1 Monoclonal Antibody Service Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Monoclonal Antibody Service Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)
5.1 Global Monoclonal Antibody Service Sales and Growth Rate (2021-2027)
5.2 Global Monoclonal Antibody Service Sales Value and Growth Rate (2021-2027)
6 Monoclonal Antibody Service Competitive Analysis
6.1 Pfizer
6.1.1 Pfizer Company Profiles
6.1.2 Pfizer Product Introduction
6.1.3 Pfizer Monoclonal Antibody Service Production, Revenue (2016-2021)
6.1.4 SWOT Analysis
6.2 Roche
6.2.1 Roche Company Profiles
6.2.2 Roche Product Introduction
6.2.3 Roche Monoclonal Antibody Service Production, Revenue (2016-2021)
6.2.4 SWOT Analysis
6.3 Eli Lilly
6.3.1 Eli Lilly Company Profiles
6.3.2 Eli Lilly Product Introduction
6.3.3 Eli Lilly Monoclonal Antibody Service Production, Revenue (2016-2021)
6.3.4 SWOT Analysis
6.4 Bayer
6.4.1 Bayer Company Profiles
6.4.2 Bayer Product Introduction
6.4.3 Bayer Monoclonal Antibody Service Production, Revenue (2016-2021)
6.4.4 SWOT Analysis
6.5 Amgen
6.5.1 Amgen Company Profiles
6.5.2 Amgen Product Introduction
6.5.3 Amgen Monoclonal Antibody Service Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6 Sanofi-Aventis
6.6.1 Sanofi-Aventis Company Profiles
6.6.2 Sanofi-Aventis Product Introduction
6.6.3 Sanofi-Aventis Monoclonal Antibody Service Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 Johnson & Johnson
6.7.1 Johnson & Johnson Company Profiles
6.7.2 Johnson & Johnson Product Introduction
6.7.3 Johnson & Johnson Monoclonal Antibody Service Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 Novo Nordisk
6.8.1 Novo Nordisk Company Profiles
6.8.2 Novo Nordisk Product Introduction
6.8.3 Novo Nordisk Monoclonal Antibody Service Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
6.9 Merck
6.9.1 Merck Company Profiles
6.9.2 Merck Product Introduction
6.9.3 Merck Monoclonal Antibody Service Production, Revenue (2016-2021)
6.9.4 SWOT Analysis
6.10 Abbott Laboratories
6.10.1 Abbott Laboratories Company Profiles
6.10.2 Abbott Laboratories Product Introduction
6.10.3 Abbott Laboratories Monoclonal Antibody Service Production, Revenue (2016-2021)
6.10.4 SWOT Analysis
6.11 GSK
6.12 BMS
6.13 Alexion
6.14 UCB
6.15 Seattle Genetics
7 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
